Skip to main content
Top
Published in:

17-04-2025 | Juvenile Rheumatoid Arthritis | ORIGINAL ARTICLE

Autoimmune/immune rheumatic diseases in family members of children with enthesitis related arthritis and other categories of juvenile idiopathic arthritis: a study from India

Authors: Lekshmi Minikumari Rahulan, Able Lawrence, Amita Aggarwal

Published in: Clinical Rheumatology | Issue 6/2025

Login to get access

Abstract

Background

Familial aggregation of autoimmune/inflammatory rheumatic diseases suggests a shared genetic basis for autoimmunity. Data on familial autoimmune/inflammatory rheumatic diseases is limited in JIA.

Methods

Accompanying family members of all consecutive patients with JIA attending the clinic during March 2023-May 2024 were asked to participate in the study. Those consenting were interviewed about the history of autoimmune/immune rheumatic diseases among the first- and second-degree relatives, with the help of a questionnaire (validated with medical records or telephonic interviews with relatives). In addition, family members of 71 healthy children served as controls.

Results

8244 relatives of 361 patients with JIA and 1033 relatives of 71 healthy controls were included in the study. Among 361 JIA patients (267 ERA, 24 systemic onset, 44 polyarticular, 12 oligoarticular and 14 psoriatic arthritis) 144 (39.8%) had at least one family member with autoimmune/immune rhematic diseases. In families of children with ERA, Spondyloarthropathy & JIA were the common disease in family while in non-ERA JIA, hypothyroidism and RA were common. First degree relatives had higher prevalence as compared to second degree relatives of patients (130/1639 versus 97/4421; p < 0.05). 2.5% maternal relatives of patients had disease as opposed to 1.9% paternal relatives of patients (p < 0.001). The risk ratio among relatives of JIA patients was 1.22, while the sibling risk ratio was 5.91.

Conclusion

Nearly 40% of JIA patients had familial autoimmune/immune rhematic diseases. While in ERA there was paternal parent of origin effect for SpA in non-ERA there was maternal parent of origin for autoimmune diseases.
Key Points
• Nearly 40% of children with JIA had familial autoimmune/immune rhematic diseases.
• In family members of children with ERA, SpA and JIA were common while in non-ERA family members hypothyroidism and RA were common.
• First degree relatives had a higher prevalence of autoimmune diseases as compared to second degree relatives.
• A possible paternal parent of origin effect was seen with spondyloarthropathy in ERA, while in non-ERA categories there was a trend towards maternal parent of origin effect.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Autoimmune/immune rheumatic diseases in family members of children with enthesitis related arthritis and other categories of juvenile idiopathic arthritis: a study from India
Authors
Lekshmi Minikumari Rahulan
Able Lawrence
Amita Aggarwal
Publication date
17-04-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 6/2025
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07444-6

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Log in / Register to watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more